Skip to main content

Table 1 Patient and disease characteristics pre-ablation

From: Anterior gland focal cryoablation: proof-of-concept primary prostate cancer treatment in select men with localized anterior cancers detected by multi-parametric magnetic resonance imaging

CharacteristicValue
PSA (ng/ml), median (IQR)8.7 (6.7, 11.76)
TRUS Prostate Volume (cc), median (IQR)35 (24.3, 47.7)
No. prior biopsy sessions, median (IQR)3 (2,3)
MRI lesion volume (mL), median (IQR): 
 Overall2 (0.86, 3.1)
 PGG 12 (0.74, 2.94)
 PGG 22.04 (0.98, 4.5)
Biopsy type:
 Fusion, No. (%)12 (71)
 TTMB, No. (%)5 (29)
No. cores, mean (range)24.8 (1, 68)
No. positive cores b (%):
 111 (64.7)
 24 (23.5)
 42 (11.8)
PGG, No. (%)
 112 (71)
 25 (29)
  1. PGG prognostic grade group, TTMB transperineal template-guided prostate mapping biopsy
  2. Includes most recent biopsy performed at Duke
  3. Most recent biopsy performed at Duke prior to cryoablation